Immunic, Inc., a biotechnology company, has announced the completion of enrollment for its phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis. The company expects to present top-line data from these trials by the end of 2026. Vidofludimus calcium, an orally available Nurr1 activator, has shown potential neuroprotective effects and aims to offer a novel treatment option for people living with relapsing multiple sclerosis. The trials will analyze confirmed disability worsening, and a pooled analysis is planned for this clinical endpoint.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY45763) on August 07, 2025, and is solely responsible for the information contained therein.